Department of Thoracic Surgery, Xingtai People's Hospital of Hebei Medical University, Xingtai, Hebei Province, China.
Department of Cardiothoracic Surgery, Jiujiang First People's Hospital, Jiujiang, Jiangxi Province, China.
Medicine (Baltimore). 2021 Aug 13;100(32):e26868. doi: 10.1097/MD.0000000000026868.
In recent years, related studies have revealed that tripartite motif-containing 59 (TRIM59) is related to the prognosis of lung cancer. However, these results have not been proved by any evidence. Therefore, this study evaluated the relationship between TRIM59 and the prognosis of lung cancer by carrying out meta-analysis. In addition, we explored the mechanism and related pathways of TRIM59 in lung cancer through bioinformatics analysis.
Comprehensive literature search was performed in China National Knowledge Infrastructure, Chinese Biomedical literature Database, Chinese Scientific and Journal Database, Wan Fang, Web of Science, PubMed, and EMBASE databases, and eligible studies were obtained based on the inclusion and exclusion criteria. The pooled hazard ratios and odds ratios were applied to assess the clinical value of TRIM59 expression for overall survival and clinicopathological features. Meanwhile, meta-analysis was conducted on the Stata 16.0. The mRNA expression level of TRIM59 in lung cancer was analyzed using Oncomine and Gene Expression Profiling Interactive Analysis (GEPIA) database. Gene Set Enrichment Analysis (GSEA) was used to predict the signaling pathways that TRIM59 might be involved in. The correlation between the expression level of TRIM59 in lung cancer and the abundance of immune cell invasion was analyzed by TIMER database. The survival analysis was verified by Kaplan-Meier Plotter database.
The results of this meta-analysis would be submitted to peer-reviewed journals for publication.
In this study, the application of meta-analysis and bioinformatics analysis will provide evidence support for the study on the prognosis and mechanism of TRIM59 in lung cancer.
近年来,相关研究表明三结构域蛋白 59(TRIM59)与肺癌的预后有关。然而,这些结果尚未得到任何证据证实。因此,本研究通过荟萃分析评估了 TRIM59 与肺癌预后的关系。此外,我们通过生物信息学分析探讨了 TRIM59 在肺癌中的作用机制及相关通路。
在中国知网、中国生物医学文献数据库、中国科学引文数据库、万方、Web of Science、PubMed 和 EMBASE 数据库中进行全面的文献检索,根据纳入和排除标准获取合格的研究。采用合并风险比和优势比评估 TRIM59 表达对总生存期和临床病理特征的临床价值。同时,在 Stata 16.0 上进行荟萃分析。使用 Oncomine 和基因表达谱交互式分析(GEPIA)数据库分析肺癌中 TRIM59 的 mRNA 表达水平。采用基因集富集分析(GSEA)预测 TRIM59 可能涉及的信号通路。通过 TIMER 数据库分析肺癌中 TRIM59 表达水平与免疫细胞浸润丰度的相关性。通过 Kaplan-Meier Plotter 数据库验证生存分析。
本荟萃分析的结果将提交给同行评议期刊发表。
本研究通过荟萃分析和生物信息学分析的应用,为 TRIM59 在肺癌中的预后和作用机制研究提供了证据支持。